Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22518594 | 0.92 | HCRTR2 (0.32) | DPP4 | |
| SCHEMBL21071923 | 0.87 | HCRTR2 (0.31) | — | |
| SCHEMBL21071924 | 0.87 | HCRTR2 (0.31) | — | |
| SCHEMBL21071925 | 0.87 | HCRTR2 (0.31) | — | |
| SCHEMBL21072335 | 0.87 | HCRTR2 (0.31) | — | |
| SCHEMBL21072336 | 0.87 | HCRTR2 (0.31) | — | |
| SCHEMBL3667379 | 0.85 | MMP2 (0.34) | — | |
| SCHEMBL29128209 | 0.81 | DPP4 (0.36) | DPP4 | |
| SCHEMBL20566560 | 0.80 | ALDH1A1 (0.30) | — | |
| SCHEMBL20570544 | 0.80 | ALDH1A1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10052330-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2018-08-21 | — | — | US | disclosed |
| EP-2718293-B1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LTD (CN) | 2017-10-25 | — | — | EP | disclosed |
| US-20160324864-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | HUTCHISON MEDIPHARMA LIMITED | 2016-11-10 | — | — | US | disclosed |
| US-9434726-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | HUTCHISON MEDIPHARMA LIMITED (CN) | 2016-09-06 | — | — | US | disclosed |
| EP-2766347-B1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-05-04 | — | — | EP | disclosed |
| US-9284298-B2 | Pyrazolyl-pyrimidine derivatives as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2016-03-15 | — | — | US | disclosed |
| US-9079929-B2 | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-07-14 | — | — | US | disclosed |
| US-9045445-B2 | Glycine transporter-1 inhibitors, methods of making them, and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2015-06-02 | — | — | US | disclosed |
| US-20140274960-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-18 | — | — | US | disclosed |
| EP-2766347-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | Bristol-Myers Squibb Company (US) | 2014-08-20 | — | — | EP | disclosed |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-7932262-B2 | Quinazolines for PDK1 inhibition | NOVARTIS AG (CH) | 2011-04-26 | — | — | US | disclosed |
| EP-2303276-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL]OXY}QUINAZOLINE | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | disclosed |
| US-7838530-B2 | Quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2010-11-23 | — | — | US | disclosed |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | NOVARTIS VACCINES & DIAGNOSTICS, INC. (US) | 2010-02-25 | — | — | US | disclosed |
| US-20090286982-A1 | NOVEL SALT-554 | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | US | disclosed |
| EP-2065369-A1 | UREA COMPOUND OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2009-06-03 | — | — | EP | disclosed |
| US-20060287295-A1 | Quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2006-12-21 | — | — | US | disclosed |
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ASTRAZENECA AB (SE) | 2005-09-29 | — | — | US | disclosed |
| US-20020013327-A1 | Compositions and methods for treating female sexual dysfunction | LEE ANDREW G (US) | 2002-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215574-A1 | 4-anilino quinazoline derivatives as antiproliferative agents | ERBB2, ERBB4, EGFR | DPP4 2770/4885 |
| US-20060287295-A1 | Quinazoline derivatives as antiproliferative agents | MKI67, CCNI, ERBB2 | DPP4 4329/4885 |
| US-20160324864-A1 | SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS | SYK, BTK, LYN | DPP4 1949/4885 |
| US-20090286982-A1 | NOVEL SALT-554 | KRAS, NISCH, WASHC4 | DPP4 693/4885 |
| US-20140274960-A1 | SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUNDS AS FACTOR XIA INHIBITORS | TFPI, TFPI2, KLKB1 | DPP4 1107/4885 |
| US-10052330-B2 | Substituted pyrido[3,4-b]pyrazines as Syk inhibitors | SYK, BTK, TYRO3 | DPP4 1497/4885 |
| US-20020013327-A1 | Compositions and methods for treating female sexual dysfunction | PDE3A, PDE3B, PDE2A | DPP4 3764/4885 |
| US-20100048561-A1 | QUINAZOLINES FOR PDK1 INHIBITION | PDK1, PDK2, PDK3 | DPP4 1662/4885 |
| US-20110172230-A1 | UREA COMPOUND OR SALT THEREOF | FAAH, FAAH2, UTS2R | DPP4 1941/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.